Today on All Access we discuss Build Back Better and its Impact on the Generic and Biosimilar Industry. My guests are Kurt Karst, Director at Hyman Phelps & McNamara, Rachel Turow, Associate General Counsel for Regulatory Law and Policy and the Head of U.S. Regulatory Policy at Teva Pharmaceuticals, and Rachel Goode, Senior Vice President for Biosimilars Patents and Legal at Fresenius Kabi.

Today we talk with CMMB president and chief executive officer, Mary Beth Powers. With a distinct focus on women and children's health all around the world, CMMB and its global network of volunteers deliver long-term care and medicines to communities in Africa, Latin America, the Caribbean and other regions affected by poverty, and who have unequal access to healthcare. The team at CMMB is helping countless thousands of people around the world turn their personal tragedies into triumphs.

Shortages of health care products, like the current baby formula situation, and consumer goods continue to bedevil the U.S. Yet, prescription medicines generally have been available with few disruptions since the start of the pandemic. How are drug shortages kept in check… and just what is a drug shortage, for that matter? Learn the facts by joining AAM CEO Dan Leonard as he speaks to eminent 3 pharmacists, each with different insights into management and mitigation of drug shortages: David Gaugh, SVP, Sciences & Regulatory Affairs, AAM, Jessica Daley, Group VP, Chief Pharmacy Officer, Premier, and Steven Schondelmeyer, professor of pharmacy at the University of Minnesota.

Direct Relief President and CEO Thomas Tighe joins CEO Dan Leonard to talk about the humanitarian support Direct Relief is providing at the request of Ukraine’s Ministry of Health in the war-torn country and to millions of its refugees in border countries. “We're so thankful for the [generic industry’s] responsiveness. They don't have to do this, it's not their job. That they did it means a lot. It means a lot for people in Ukraine.”

Today we're here in Orlando, Florida during our Annual Meeting, ACCESS! We're talking with Alok Sonig, CEO, US Generics, and Head of Global R&D & Biosimilars at Lupin Incorporated.

Our guest today is Kendra Davenport, the chief development officer for Operation Smile. Operation Smile is one of the largest volunteer surgical nonprofits in the world and an AAM member company. The team does far more than just change a child's smile, it truly transforms their life.

Dispensary of Hope is our featured company on today's program. And joining me to talk about their efforts, their mission is Dispensary of Hope Chief Executive Officer, Mr. Chris Palombo.

October is National Pharmacists Month. And today we have special guests who are also individuals that I'm very proud to call colleagues. At AAM, we're very proud to have three pharmacists on staff and I'm joined by two of them here today. Lisa Parks and Monét Stanford.

In celebration Hatch-Waxman's anniversary, All Access the podcast and ATS, that's Allies, Thinkers & Scribes, welcomes industry veteran and generics expert, Robert Pollock. Bob worked at FDA in the earliest days of Hatch-Waxman and was among the very first employees of the new division of generic drugs - a real pioneer in the regulatory side of our industry.

Today on All Access we speak with Doug Long, vice president of industry relations at IQVIA. IQVIA is a global leader in the use of data, technology and advanced analytics to help customers drive healthcare forward.